Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroids vs G-CSF in Severe Alcoholic Hepatitis
NCT04066179Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of filgrastim in alcoholic hepatitis (AH) (3 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Improvement in Survival at 90 days. Status: unknown.
02
Drugs
filgrastim
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT04066179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066179.